|
|
|
|
| |
|
|
| Castro,José Alberto; Montalto de Mecca,María; Díaz Gómez,María Isabel; Castro,Gerardo Daniel. |
| La quimioterapia de la enfermedad de Chagas cuenta en la actualidad con el empleo de dos fármacos solamente: Nifurtimox y Benznidazol. Nifurtimox es un nitrofurano y Benznidazol es un compuesto nitroimidazólico. El uso de estas drogas para tratar la fase aguda de la enfermedad se acepta ampliamente. Sin embargo, su utilización en el tratamiento de la fase crónica no está exenta de cuestionamientos serios. Los efectos colaterales de ambas son un inconveniente mayor en su uso, y frecuentemente fuerza a los médicos a detener el tratamiento. Los estudios de toxicidad experimentales con Nifurtimox evidenciaron neurotoxicidad, daño testicular, toxicidad ovárica y efectos deletéreos en corazón, tejido mamario, adrenales, colon y esófago. Para el Benznidazol, se... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Benznidazol; Nifurtimox; Enfermedad de Chagas; Quimioterapia; Quimioprofilaxis; Violeta de Genciana; Tripanosomiasis americana. |
| Ano: 2015 |
URL: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572015000100009 |
| |
|
|
| MAYA,JUAN DIEGO; RODRÍGUEZ,ANDRÉS; PINO,LAURA; PABÓN,ADRIANA; FERREIRA,JORGE; PAVANI,MARIO; REPETTO,YOLANDA; MORELLO,ANTONIO. |
| Proteins rich in sulfhydryl groups, such as metallothionein, are present in several strains of the parasite Trypanosoma cruzi, the etiological agent of Chagas' disease. Metallothionein-like protein concentrations ranged from 5.1 to 13.2 pmol/mg protein depending on the parasite strain and growth phase. Nifurtimox and benznidazole, used in the treatment of Chagas' disease, decreased metallothionein activity by approximately 70%. T. cruzi metallothionein was induced by ZnCl2. Metallothionein from T. cruzi was partially purified and its monobromobimane derivative showed a molecular weight of approximately 10,000 Da by SDS-PAGE analysis. The concentration of trypanothione, the major glutathione conjugate in T. cruzi, ranged from 3.8 to 10.8 nmol/mg protein,... |
| Tipo: Journal article |
Palavras-chave: Trypanosoma cruzi; Metallothionein; Glutathione; Trypanothione; Benznidazole; Nifurtimox; Buthionine sulfoximine. |
| Ano: 2004 |
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602004000100007 |
| |
|
| |
|
|
| Maya,Juan Diego; Orellana,Myriam; Ferreira,Jorge; Kemmerling,Ulrike; López-Muñoz,Rodrigo; Morello,Antonio. |
| There are approximately 7.8 million people in Latin America, including Chile, who suffer from Chagas disease and another 28 million who are at risk of contracting it. Chagas is caused by the flagellate protozoan Trypanosoma cruzi. It is a chronic disease, where 20%-30% of infected individuals develop severe cardiopathy, with heart failure and potentially fatal arrhythmias. Currently, Chagas disease treatment is more effective in the acute phase, but does not always produce complete parasite eradication during indeterminate and chronic phases. At present, only nifurtimox or benznidazole have been proven to be superior to new drugs being tested. Therefore, it is necessary to find alternative approaches to treatment of chronic Chagas. The current treatment... |
| Tipo: Journal article |
Palavras-chave: Chagas disease; Chemotherapy; Nifurtimox; Trypanosoma cruzi; Prostaglandins. |
| Ano: 2010 |
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602010000300009 |
| |
|
|
|
